fashion -WSS

fashion

author：hotspot 2025-08-11 08:01:06 - browse：2978

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Hospitals are piloting generative AI tools as regulators play catch

explore

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

Grail spinoff by Illumina should end disastrous merger attempt

As AI regulations shape up, health tech startups beg for clarity

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Ukraine seeks to reclaim its role as a hub for clinical trials

Researchers tackle phage therapy hurdles for wider adoption

hotspot

fashion

A looming test for neoantigen cancer vaccines

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare drug price negotiation hasn't dried up venture capital

After affirmative action ruling, medical educators look to 'holistic review'

Reporting on presidential health from Reagan to Trump and Biden

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Anesthesiologist group: stop taking Ozempic before surgery

Three trends to watch in biotech in 2024

Virginia high school admissions case could be legal follow

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Wikipedia

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

What STAT readers think about the FDA and patient advocacy

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Why health records don't always know when patients are dead

How to keep neuroscience’s past racism from being its future

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

explore

focus

hotspot

focus